MANILA, Philippines — The Food and Drug Administration (FDA) has granted Covaxin, the COVID-19 vaccine developed by India’s Bharat Biotech, an emergency use authorization (EUA).
FDA Director-General Eric Domingo on Tuesday said the country’s experts, upon studying the drugmaker’s data on its clinical trials, found that the benefit of administering the Covaxin “outweighs its risks.”
“They initially applied with us noong Jan. 22. Noong March 9 binigay po nila sa atin ‘yung kanilang clinical trial data at ‘yun ang tiningnan ng ating experts and they decided that the benefit of this outweighs the risks,” he said in a Laging Handa public briefing.
…
Keep on reading: India’s COVID-19 vaccine Covaxin granted emergency use authorization